Department of Clinical Pulmonology, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia
Mini Review
Galectin-3: A Potential Biomarker and Therapeutic Target in Severe COVID-19
Author(s): Herooety Feroojer*
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has posed unprecedented challenges to global public health. While the
majority of COVID-19 cases exhibit mild symptoms, a subset of patients develops severe respiratory distress, multi-organ failure and even death.
Identifying biomarkers associated with disease severity is crucial for prognosis and developing targeted therapies. Recent research suggests that
elevated levels of Galectin-3 may play a significant role in the pathogenesis of severe COVID-19. Galectin-3 is a β-galactoside-binding lectin
involved in various physiological and pathological processes, including inflammation, fibrosis and immune regulation. It is expressed by various
immune cells, endothelial cells and epithelial cells and its dysregulation has been implicated in numerous diseases, including cancer, heart failure
.. Read More»
DOI:
10.37421/2472-1247.2024.10.288
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 